Bokf Na Boosts Holdings in Innoviva, Inc. (NASDAQ:INVA)

Bokf Na lifted its stake in Innoviva, Inc. (NASDAQ:INVA) by 180.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,377 shares of the biotechnology company’s stock after purchasing an additional 29,846 shares during the period. Bokf Na owned 0.07% of Innoviva worth $761,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Westfield Capital Management Co. LP lifted its position in Innoviva by 27.8% during the 4th quarter. Westfield Capital Management Co. LP now owns 2,614,127 shares of the biotechnology company’s stock valued at $41,931,000 after acquiring an additional 569,117 shares during the period. American Century Companies Inc. lifted its position in Innoviva by 369.6% during the 2nd quarter. American Century Companies Inc. now owns 459,690 shares of the biotechnology company’s stock valued at $7,539,000 after acquiring an additional 361,797 shares during the period. Hillsdale Investment Management Inc. purchased a new position in Innoviva during the 4th quarter valued at about $4,663,000. CWA Asset Management Group LLC purchased a new position in Innoviva during the 4th quarter valued at about $4,070,000. Finally, Boston Partners lifted its position in Innoviva by 90.3% during the 1st quarter. Boston Partners now owns 391,456 shares of the biotechnology company’s stock valued at $5,966,000 after acquiring an additional 185,784 shares during the period. 99.12% of the stock is owned by hedge funds and other institutional investors.

Innoviva Stock Up 1.0 %

Shares of Innoviva stock opened at $19.81 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 11.40 and a current ratio of 12.70. The stock has a market capitalization of $1.24 billion, a PE ratio of 8.92 and a beta of 0.57. Innoviva, Inc. has a 52-week low of $12.22 and a 52-week high of $19.87. The company has a 50-day simple moving average of $18.41 and a two-hundred day simple moving average of $16.48.

Innoviva (NASDAQ:INVA) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported $0.68 earnings per share (EPS) for the quarter. The business had revenue of $99.90 million during the quarter. Innoviva had a net margin of 44.00% and a return on equity of 33.26%. On average, analysts anticipate that Innoviva, Inc. will post 0.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

INVA has been the subject of a number of recent research reports. StockNews.com cut shares of Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Innoviva in a research report on Tuesday, July 30th.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.